Strategic partnerships SciNeuro has secured and is pursuing exclusive worldwide licensing collaborations for its amyloid beta targeted antibody program, presenting a clear opportunity to engage with CDMO partners, contract research organizations, and large pharma seeking to expand neurodegeneration portfolios.

Financing momentum With ongoing funding rounds totaling over 100 million and a recent 53 million equity financing, there is appetite for strategic investors and co-development deals that align with their pipeline funding needs and accelerate IND and clinical milestone targets.

Key disease focus The company concentrates on neurodegenerative diseases, including Alzheimer’s and Parkinson’s, through mechanisms like neurovascular inflammation, proteinopathy, and immune response—positioning opportunities for partners with CNS targets, biomarker programs, or companion diagnostics.

Grant support Recent MJFF grant support for the LRRK2-targeted ASO program signals readiness for preclinical-to-IND progression, suggesting a path for grant-backed collaborations, milestone-based funding, and accelerated development timelines.

Executive and structure With a growing leadership team including a newly appointed Chief Financial Officer and a focused biotech footprint in Rockville, SciNeuro presents a lean partner for early-stage licenses, strategic co-development, and joint ventures with balanced risk and potential upside.